The FDA has granted 501 (k) clearance to the EXENT® System, a fully automated device for assessing monoclonal gammopathies, ...

The FDA has accepted the new drug application (NDA) of the synthetic, targeted radiotherapeutic agent 177 Lu-edotreotide (ITM ...

At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Meara explored the ...

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...

Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...

Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...

In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...

The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...

The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...